Physician profile
Feng Wang
NPI 1922283431
$2,417.86
in general payments reported to CMS, 2019-2025
19 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2023: $257 · 2024: $353 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,200.26 | 2021-2025 | Cardiomems, Freestyle Libre 3, Mitraclip |
| Angiodynamics, INC. | $203.95 | 2025 | Alphavac |
| Heartflow, INC. | $132.75 | 2025 | |
| Novartis Pharmaceuticals Corporation | $117.94 | 2025 | |
| Philips North America LLC | $113.35 | 2024 | (Bk5) Azurion 5 M20 |
| Bridgebio Pharma, INC. | $107.56 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $83.90 | 2025 | |
| Boston Scientific Corporation | $79.40 | 2025 | Vigilant X4 Crt-D, Accolade Sr, Patientcare Link |
| Cleerly, INC. | $69.95 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Pfizer INC. | $60.27 | 2025 | |
| Scpharmaceuticals INC. | $51.33 | 2025 | |
| Amgen INC. | $45.04 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.14 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $31.68 | 2025 | Amvuttra |
| Novo Nordisk INC | $27.92 | 2025 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.42 | 2025 | Camzyos |
| Bracco Diagnostics INC. | $20.11 | 2025 | |
| Edwards Lifesciences Corporation | $13.89 | 2023 | Sapien 3 Ultra Resilia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.